Efficacy and Safety Profile of CPX-351 in Secondary Acute Myeloid Leukemia (sAML): A Systematic Review

被引：0
|
作者：
Ibrahim, Ahmed [1 ]
Yousaf, Muhammad Abdullah [1 ]
Ikram, Mariam [2 ]
Khalid, Huma
Anum [3 ]
Safdar, Omar A. [4 ]
Anwer, Zain [5 ]
Faraz, Fatima [1 ]
Rehman, Mohammad [1 ]
Saad, Muhammad [2 ]
机构：
[1] Rawalpindi Med Univ, Rawalpindi, Pakistan
[2] Shifa Int Hosp Ltd, Islamabad, Pakistan
[3] Faisalabad Med Univ, Faisalabad, Pakistan
[4] Univ Arizona, Tucson, AZ USA
[5] Cleveland Clin, Cleveland, OH USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-187301
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] CPX-351 in Patients with Newly Diagnosed Post Myeloproliferative Neoplasms Acute Myeloid Leukemia
    Garciaz, Sylvain
    Belhabri, Amine
    Guieze, Romain
    Goursaud, Laure
    Peterlin, Pierre
    Ledoux, Marie-Pierre
    Mathilde, Hunault-Berger
    Chebrek, Safia
    Robin, Jean-Baptiste
    Pigneux, Arnaud
    Bonnet, Sarah
    Bonmati, Caroline
    Bertoli, Sarah
    Braun, Thorsten
    Chantepie, Sylvain
    Meunier, Mathieu
    Heiblig, Mael
    Cluzeau, Thomas
    Jourdan, Eric
    Villate, Alban
    Recher, Christian
    Vey, Norbert
    Rey, Jerome
    BLOOD, 2023, 142
  • [22] Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia
    Talati, Chetasi
    Goldberg, Aaron D.
    Desai, Pinkal
    Chan, Onyee
    Famulare, Christopher
    Komrokji, Rami S.
    Kuykendall, Andrew T.
    Fernandez, Hugo F.
    Deutsch, Yehuda E.
    Padron, Eric
    List, Alan F.
    Lancet, Jeffrey E.
    Roboz, Gail J.
    Tallman, Martin S.
    Sallman, David A.
    Sweet, Kendra L.
    BLOOD, 2018, 132
  • [23] Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351)
    Salhotra, Amandeep
    Ngo, Dat
    Zhang, Jianying
    Sandhu, Karamjeet S.
    Al Malki, Monzr M.
    Aribi, Ahmed
    Ali, Haris
    Koller, Pkoller
    Arslan, Shukaib
    Artz, Andrew S.
    Budde, Lihua E.
    Khaled, Samer
    Dadwal, Sanjeet S.
    Snyder, David S.
    Forman, Stephen J.
    Nakamura, Ryotaro
    Stein, Anthony S.
    Marcucci, Guido
    Aldoss, Ibrahim
    Pullarkat, Vinod A.
    BLOOD, 2020, 136
  • [24] Real World Outcomes of CPX-351 Compared to Traditional Chemotherapy with Cytarabine Consolidation for Treatment of Secondary Acute Myeloid Leukemia
    Granger, Katelynn
    Gaffney, Kelly J.
    Smith, Deidra
    Weeda, Erin
    Baratam, Praneeth
    Green, Kimberly Michelle
    Coltoff, Alexander
    Davis, James A.
    BLOOD, 2023, 142
  • [25] Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML)
    Kadia, Tapan M.
    Borthakur, Gautam
    Takahashi, Koichi
    DiNardo, Courtney D.
    Daver, Naval
    Pemmaraju, Naveen
    Jabbour, Elias
    Jain, Nitin
    Short, Nicholas J.
    Qiao, Wei
    Adewale, Lade
    Rausch, Caitlin R.
    Pierce, Sherry A.
    Alvarado, Yesid
    Alousi, Amin M.
    Popat, Uday R.
    Khouri, Issa F.
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Cortes, Jorge E.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    BLOOD, 2020, 136
  • [26] Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
    Matthews, Andrew H.
    Perl, Alexander E.
    Luger, Selina M.
    Loren, Alison W.
    Gill, Saar I.
    Porter, David L.
    Babushok, Daria V.
    Maillard, Ivan P.
    Carroll, Martin P.
    Frey, Noelle V.
    Hexner, Elizabeth O.
    Martin, Mary Ellen
    McCurdy, Shannon R.
    Stadtmauer, Edward A.
    Paralkar, Vikram R.
    Bruno, Ximena Jordan
    Hwang, Wei -Ting
    Margolis, David
    Pratz, Keith W.
    BLOOD ADVANCES, 2022, 6 (13) : 3997 - 4005
  • [27] Real-world experience with CPX-351 in high-risk acute myeloid leukemia
    Lemoli, Roberto M.
    Montesinos, Pau
    Jain, Akriti
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 185
  • [28] TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia
    Goldberg, Aaron D.
    Talati, Chetasi
    Desai, Pinkal
    Famulare, Christopher
    Devlin, Sean M.
    Farnoud, Noushin
    Sallman, David A.
    Lancet, Jeffrey E.
    Roboz, Gail J.
    Sweet, Kendra L.
    Tallman, Martin S.
    BLOOD, 2018, 132
  • [29] Efficacy and Safety of CPX-351 Versus 7+3 in Older Adults with Secondary Acute Myeloid Leukemia: Combined Subgroup Analysis of Phase 2 and Phase 3 Studies
    Lancet, Jeffrey E.
    Ritchie, Ellen K.
    Uy, Geoffrey L.
    Medeiros, Bruno C.
    Newell, Laura F.
    Lin, Tara L.
    Hogge, Donna
    Stuart, Robert K.
    Strickland, Stephen A.
    Solomon, Scott R.
    Stone, Richard M.
    Kolitz, Jonathan E.
    Bixby, Dale L.
    Schiller, Gary J.
    Wieduwilt, Matthew J.
    Kovacsovics, Tibor
    Ryan, Robert J.
    Chiarella, Michael
    Louie, Arthur C.
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [30] Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML) with Prior Hypomethylating Agent (HMA) Exposure Who Achieved Remission
    Lin, Tara
    Ryan, Daniel H.
    Ritchie, Ellen K.
    Strickland, Stephen A.
    Hogge, Donna E.
    Solomon, Scott R.
    Kolitz, MDJonathan E.
    Schiller, Caryl
    Wieduwilt, Matthew J.
    Ryan, Robert J.
    Fader, Stefan
    Cortes, Jorge E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S102 - S102
12345